- Home
- PCF vs TLSI Comparison
PCF vs TLSI Comparison
Compare PCF & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCF
- TLSI
- Stock Information
- Founded
- PCF 1987
- TLSI 2010
- Country
- PCF United States
- TLSI United States
- Employees
- PCF N/A
- TLSI N/A
- Industry
- PCF Trusts Except Educational Religious and Charitable
- TLSI Medical Specialities
- Sector
- PCF Finance
- TLSI Health Care
- Exchange
- PCF Nasdaq
- TLSI Nasdaq
- Market Cap
- PCF 196.9M
- TLSI 160.4M
- IPO Year
- PCF N/A
- TLSI N/A
- Fundamental
- Price
- PCF $6.34
- TLSI $5.22
- Analyst Decision
- PCF
- TLSI Strong Buy
- Analyst Count
- PCF 0
- TLSI 5
- Target Price
- PCF N/A
- TLSI $10.90
- AVG Volume (30 Days)
- PCF 74.8K
- TLSI 41.0K
- Earning Date
- PCF 01-01-0001
- TLSI 05-15-2025
- Dividend Yield
- PCF 10.90%
- TLSI N/A
- EPS Growth
- PCF N/A
- TLSI N/A
- EPS
- PCF N/A
- TLSI N/A
- Revenue
- PCF N/A
- TLSI $32,141,000.00
- Revenue This Year
- PCF N/A
- TLSI $55.13
- Revenue Next Year
- PCF N/A
- TLSI $50.71
- P/E Ratio
- PCF N/A
- TLSI N/A
- Revenue Growth
- PCF N/A
- TLSI 46.20
- 52 Week Low
- PCF $5.71
- TLSI $3.50
- 52 Week High
- PCF $6.96
- TLSI $7.55
- Technical
- Relative Strength Index (RSI)
- PCF 51.15
- TLSI 45.69
- Support Level
- PCF $6.16
- TLSI $4.96
- Resistance Level
- PCF $6.43
- TLSI $5.47
- Average True Range (ATR)
- PCF 0.08
- TLSI 0.36
- MACD
- PCF 0.00
- TLSI -0.01
- Stochastic Oscillator
- PCF 59.26
- TLSI 31.51
About PCF High Income Securities Fund
High Income Securities Fund is a closed-end management investment company. Its primary objective is to provide high current income and capital appreciation is the secondary objective. The Fund pursues its objective primarily by investing in both convertible bonds and convertible preferred stocks. The Fund also invests significantly in high-yielding non-convertible securities with the potential for capital appreciation.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.